17-phenyl trinor Prostaglandin F2(alpha) EIA Kit

17-phenyl trinor PGF2(alpha) is a metabolically stable analog of PGF2(alpha) and is a potent agonist for the FP receptor. The ethyl amide analog has been approved for use as an ocular hypotensive drug, sold under the Allergan trade name Bimatoprost. There is some evidence that unmetabolized 17-phenyl trinor PGF2(alpha) ethyl amide is a weak FP receptor agonist. 17-phenyl trinor PGF2(alpha) ethyl amide is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 microg/g corneal tissue/24 hours. Cayman's 17-phenyl trinor PGF2(alpha) EIA is a sensitive detection method for measuring both the free acid and ethyl amide forms of 17-phenyl trinor PGF2(alpha). The assay is most appropriate for use when only one of the two forms is present. Samples containing mixtures of both the ethyl amide and free acid should be purified and the two compounds separated prior to EIA analysis.

Prices direct from Cayman Chemical Company

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

516821

Form

96 Well

P Type

Assay Kits|Prostaglandins|Eicosanoids

Weight

0

Storage Temp

-20

Shipping Temp

-20

Additional Info

17-phenyl trinor Prostaglandin F2(alpha) (17-phenyl trinor PGF2(alpha)) is a metabolically stable analog of PGF2(alpha) and is a potent agonist for the FP receptor. It binds to the FP receptor on ovine luteal cells with a relative potency of 756% compared to that of PGF2(alpha). At the rat recombinant FP receptor expressed in CHO cells, 17-phenyl trinor PGF2(alpha) inhibits PGF2(alpha) binding with a Ki value of 1.1 nM. In human and animal models of glaucoma, FP receptor agonist activity corresponds very closely with intraocular hypotensive activity. 17-phenyl trinor PGF2(alpha) ethyl amide is an F-series prostaglandin analog which has been approved for use as an ocular hypotensive drug, sold under the Allergan trade name Bimatoprost. Whether 17-phenyl trinor PGF2(alpha) ethyl amide is a prodrug analogous to prostaglandin ester prodrugs such as latanoprost is currently controversial. There is some evidence that unmetabolized 17-phenyl trinor PGF2(alpha) is a weak FP receptor agonist. 17-phenyl trinor PGF2(alpha) is converted by an amidase enzymatic activity in the bovine and human cornea to yield the corresponding free acid, with a conversion rate of about 40 microg/g corneal tissue/24 hours. Cayman's 17-phenyl trinor PGF2(alpha) EIA is a sensitive detection method for measuring both the free acid and ethyl amide forms of 17-phenyl trinor PGF2(alpha). The assay is most appropriate for use when only one of the two forms is present. Samples containing mixtures of both the ethyl amide and free acid should be purified and the two compounds separated prior to EIA analysis.